AB-1009
/ Bayer, AskBio, Genethon
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 16, 2025
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: AskBio Inc
New P1/2 trial • Gene Therapies • Pompe Disease
January 08, 2026
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: AskBio Inc | Not yet recruiting ➔ Recruiting
Enrollment open • Gene Therapies • Pompe Disease
1 to 2
Of
2
Go to page
1